PMV Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO PMV Pharmaceuticals is David Mack, benoemd in Jul2013, heeft een ambtstermijn van 11.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.21M, bestaande uit 26.5% salaris en 73.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.25% van de aandelen van het bedrijf, ter waarde $ 1.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 3.8 jaar.
Belangrijke informatie
David Mack
Algemeen directeur
US$2.2m
Totale compensatie
| Percentage CEO-salaris | 26.5% |
| Dienstverband CEO | 11.3yrs |
| Eigendom CEO | 1.3% |
| Management gemiddelde ambtstermijn | 3.7yrs |
| Gemiddelde ambtstermijn bestuur | 3.8yrs |
Recente managementupdates
Recent updates
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Aug 04
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25PMV Pharmaceuticals reports Q3 results
Nov 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$65m |
| Dec 31 2023 | US$2m | US$586k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$4m | US$564k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$72m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$65m |
| Dec 31 2021 | US$4m | US$545k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$50m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$1m | US$495k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$27m |
| Dec 31 2019 | US$628k | US$461k | -US$25m |
Compensatie versus markt: De totale vergoeding ($USD 2.21M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).
Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
David Mack (62 yo)
11.3yrs
Tenure
US$2,209,795
Compensatie
Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$2.21m | 1.25% $ 1.0m | |
| Co-Founder | 11.8yrs | US$220.27k | 0.79% $ 659.8k | |
| Chief Development Officer | 5.4yrs | US$1.10m | 0.044% $ 36.6k | |
| Chief Financial Officer | less than a year | geen gegevens | 0.012% $ 9.9k | |
| General Counsel | 4.3yrs | geen gegevens | geen gegevens | |
| Senior VP and Head of Corporate Development & Investor Relations | 3.2yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resources | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Drug Discovery & CMC | no data | geen gegevens | geen gegevens | |
| Senior VP and Head of Clinical Development & Medical Affairs | 1.5yrs | geen gegevens | geen gegevens | |
| VP & Head of Clinical Operations | no data | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PMVP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$2.21m | 1.25% $ 1.0m | |
| Co-Founder | 11.4yrs | US$220.27k | 0.79% $ 659.8k | |
| Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 2yrs | US$124.27k | geen gegevens | |
| Independent Chairman of the Board of Directors & Member of Scientific Advisory Board | 4.4yrs | US$176.77k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director & Chair of Clinical Advisory Board | 3.6yrs | US$133.27k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.27k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$127.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PMVP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).